Harmony Biosciences Holdings, Inc.
HRMY
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmonyā¦ read more
Healthcare
Biotechnology
5 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$35.16
Price-0.23%
-$0.08
1Y
Price
Market Cap
$2.036b
Mid
Price/Earnings 3y Avg5y Avg
14.2x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+22.7%
EBITDA Margin+15.1%
Net Profit Margin+12.9%
Free Cash Flow Margin+22.7%
EBITDA Margin+15.1%
Net Profit Margin+12.9%
Free Cash Flow MarginRevenue
$899.107m
+3.5%
1y CAGR+16.0%
3y CAGR+20.2%
5y CAGREarnings
$145.615m
-8.2%
1y CAGR+4.6%
3y CAGR-3.8%
5y CAGREPS
$2.48
-8.5%
1y CAGR+5.8%
3y CAGR-2.7%
5y CAGRBook Value
$910.349m
$1.272b
Assets$361.475m
Liabilities$206.515m
DebtDebt to Assets
16.2%
0.9x
Debt to EBITDAFree Cash Flow
$341.790m
-1.8%
1y CAGR+19.1%
3y CAGR+27.3%
5y CAGRNo items found.
Press Releases
Statements and updates from the company